The third week of February brings a wide-ranging set of updates across GI oncology, reflecting continued progress in both biological stratification and clinical implementation. This week’s highlights span the care continuum—from colorectal cancer screening strategies and liquid biopsy integration to mechanistic insights into BRAFV600E resistance, metabolically defined pancreatic cancer subtypes, and perioperative immunotherapy in gastroesophageal malignancies.
Emerging evidence in early-onset colorectal cancer, POLE-mutant GI tumors, and appendiceal adenocarcinoma further underscores how increasingly granular molecular characterization is reshaping long-held clinical assumptions. Collectively, these updates point to a broader shift in GI oncology—from static genomic labeling toward functional profiling, dynamic biomarkers, and biology-driven therapeutic selection.